Ocriplasmin "major added value" for VMT treatment

Article

Jetrea, developed by ThromboGenics, offers ?major added value? for the treatment of vitreomacula traction and macular hole, claims the German Institute for Quality and Efficiency in Health Care (IQWiG).

Jetrea, developed by ThromboGenics, offers “major added value” for the treatment of vitreomacula traction and macular hole, claims the German Institute for Quality and Efficiency in Health Care (IQWiG).

Jetrea contains the active substance ocriplasmin and is administered through one intravitreal injection in adults with VMT and macular hole of a diameter less than or equal to 400 microns.

The treatment breaks down the protein fibres, which cause abnormal traction between the vitreous and the macula that causes VMT. It then releases traction and helps to complete vitreous detachment from the macula.

Dr Patrick De Haes, CEO of ThromboGenics, stated, “IQWiG’s assessment confirming the significant additional benefits of Jetrea for VMT validates the importance of our novel drug in treating patients with this major sight-threatening disease.”

“For the first time, patients can be treated at an earlier stage of their disease, rather than having to watch and wait until their symptoms worsen,” continued Dr De Haes. “We, and our partner Alcon, look forward to working with G-BA to ensure that the positive benefits shown by Jetrea are reflected in its final guidance.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.